logo-loader
viewOptiBiotix Health PLC

OptiBiotix Health building a commercial head of steam

“As existing deals contribute to full-year revenues, partners continue to grow sales with new product launches, and as new agreements continue to be signed we anticipate further revenue growth in 2019,” said chief executive, Stephen O’Hara

woman measuring her midriff
Weight loss ingredient SlimBiome won a coveted award at the Food Matters event

OptiBiotix Health PLC (LON:OPTI) said expects commercial traction and revenues to grow after signing a raft of deals for its health products.

Having developed new strains of bacteria that target gut microbiome to tackle conditions such as high cholesterol, diabetes and obesity, it has seen significant commercial demand for its technology.

“We look forward to converting this interest into agreements in new territories and application areas in the months ahead to continue rapidly growing revenues in this new and exciting area of science which has the potential to revolutionise the future of healthcare,” said the company in a statement summarising the 12 months ended November 30 last year.

Among the highlights was a five-year deal with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply supplements and drug products containing OptiBiotix’s LPLDL bacteria strain in India.

It also gas an exclusive agreement with a US company for the LPLDL that carries six-figure milestone payments.

Coveted award

Weight loss ingredient SlimBiome, meanwhile, won a coveted award at the Food Matters event.

Commercial and critical success has been backed up by a growing body of work that essentially burnishes the scientific credential of its microbiome-targeting technology.

“As existing deals contribute to full-year revenues, partners continue to grow sales with new product launches, and as new agreements continue to be signed we anticipate further revenue growth in 2019,” said chief executive, Stephen O’Hara.

In the last financial, turnover grew 543% half-on-half and 169% year-on-year to £191,000. As is common for a company at this formative stage of its commercial development, OptiBiotix was loss-making. The operating loss was just under £1.5mln, £627,906 less than the year earlier as administrative expenses fell 17.5%.

At the period-end the firm had £1.33mln, rising to £1.67mln following the reclamation of R&D tax credits. In December it raised £1.025mln via a convertible loan in preparation for the potential float of the company’s ProBiotic Health arm. OptiBiotix confirmed it is still mulling the potential demerger.

Quick facts: OptiBiotix Health PLC

Price: 53 GBX

AIM:OPTI
Market: AIM
Market Cap: £45.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

OptiBiotix Health growing its ProBiotix Health commercial team in Europe

Steve Prescott, CEO of OptiBiotix Health PLC's (LON:OPTI) ProBiotix Health division, speaks to Proactive London while in Europe to meet with some of their key customers and suppliers. Prescott updates on discussions he's having with a major European probiotic company about a new product as...

3 days, 14 hours ago

2 min read